Tag: AI

The Cover Story features the India’s 10 Biggest Bioscience Stories of the year 2024. Read interviews of Supriya Kashikar, Founder & CEO, GeNext Genomics; and Ankit Alok Bagaria, Co- Founder, Loopworm. Expert Insights by Niteen Tulpule, Director, Orthobiologix Biotech; Chander Shekhar Sibal, Vice President & Head of Division, Medical Systems Division, FUJIFILM India; and Nilesh Aggarwal, CEO, IJCP Group & Founder, Medtalks.

As per a report by APACMed and Bain & Company, the real AI opportunity in Asia-Pacific’s medtech industry lies in its ability to tailor and advance solutions to meet local market demands

Telangana is at the forefront of leveraging AI to revolutionize healthcare, making it more accessible, efficient and affordable to its citizens

Harish Bisam, Founder & Managing Director, Bisam Pharmaceuticals shares insights on his company’s trademark, Quick Vitals, the world's first AI and deep learning powered health monitoring app

The workshop opened with a perspective talk by Dr. Anand Deshpande, Founder and Chairman of Persistent Systems, who highlighted the massive $208 billion potential AI holds in healthcare by 2030

The Cover Story tracks the strides made by the Indian biotech industry towards sustainability goals. Special interview of Shivaji Dashrath Jadhav, Vice President & Head - EHS & Sustainability, Aragen Life Sciences. Expert Insights by Vikrant Agrawal, Co-founder, Care.fi and Rajeev Taneeja, Founder and CEO, Global Care. Special stories on bio-manufacturing, healthcare innovation and agri-foodtech.

The first day of the event centred around critical dialogues on healthcare accreditation, diagnostic innovation, the role of AI in transforming healthcare, and navigating the intricate legal landscape within the sector

Dermalyser support tool has already demonstrated 100% sensitivity and 93% specificity for detecting invasive melanomas

The Indian market for AI in healthcare is set to reach USD 1.6 billion by 2025, with a compound annual growth rate (CAGR) of 40.5%

The company is set to expand diagnostic and treatment capabilities in Tier 2, 3, and 4 cities